New guidance contains appropriate caution but an insufficient implementation framework ...

Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...

Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...

The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening. Fecal immunochemical test (FIT), FIT-DNA test and CEA assay are also in vitro diagnostic ...

Please provide your email address to receive an email when new articles are posted on . CMS will use newly defined criteria to qualify noninvasive biomarker CRC screening tests for coverage. Concerns ...

cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...